- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05935878
Cemented Versus Cementless Unicompartmental Knee Arthroplasty
Cemented Versus Cementless Unicompartmental Knee Arthroplasty (UKA) - A Single-blind Randomised Controlled Trial
Unicompartmental knee replacement for selected cases of osteoarthritis is less invasive than total knee replacement. It gives better range of movement; patients stay for shorter time in the hospital and have a more natural feel than total knee replacement. Usually, the implant is fixed in the bone using bone cement. However, there are potential disadvantages of using bone cement. The operation takes longer; cement can get squeezed out into the surrounding tissues and may interfere with function. To avoid these problems, the implant can be fixed without cement. Cementless components have a special coating to encourage bone in-growth and fixation. Although the investigators believe cementless fixation will be at least as good as cemented fixation, there is a risk that it could be worse and might result in loosening.
The aim of this study is therefore to compare the outcome of cemented and cementless unicompartmental knee replacement.
Study Overview
Status
Conditions
Detailed Description
Design: A prospective, randomised trial to compare the outcome of cemented and cementless unicompartmental knee replacement.
Size: 40 subjects in total will be recruited with 20 in each arm.
Methods: Patients will be recruited from the routine waiting list for unicompartmental knee replacement at the Nuffield Orthopaedic Centre. All subjects will have the procedure explained and be fully consented prior to the procedure.
Randomisation: Patients will be randomly allocated to receive either a cemented or cementless Oxford Unicompartmental Knee Replacement. This will be performed using a randomisation program based on optimisation (Minim). Subjects will be stratified according to sex and age.
Operation: All subjects will undergo the same surgical approach. 0.8mm Tantalum marker balls will be placed at standardised sites on the femur and tibia in all cases. All cemented components will be secured using the same cement. Cementless components have a hydroxy-appatite coating to facilitate bone ingrowth.
Follow-up: All patients will be followed up at 0, 3, 6, 12, 24, 60, and 120 months with clinical and radiological assessment. Clinical assessment will involve documentation with the Oxford Knee Score. Patients will undergo radiostereometric analysis and fluoroscopy to study implant migration and occurence of radiolucency, respectively.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Healthy Subjects with osteoarthritis of knee fulfilling the standard indications for an Oxford Unicompartmental Knee Replacement.
- American Society of Anaesthesiologists (ASA) Score of 1 to 3.
Exclusion Criteria:
- Subjects with severe limiting systemic illness (i.e. ASA > 3).
- Subjects who are too large for radiostereometric analysis to be carried out.
- Subjects who have had previous open surgery or anterior cruciate ligament (ACL) reconstruction on the same knee.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cementless Oxford Unicompartmental Knee Arthroplasty
Phase III Cementless Oxford Unicompartmental Knee Replacement (Biomet)
|
All patients will undergo the same surgical approach.
0.8mm diameter tantalum marker balls will be placed in the tibia and femur in all cases.
Cementless components have a hydroxy-appatite coating to facilitate bone ingrowth.
The cementless femoral component also has a smaller second peg, located anteriorly to the larger central peg that is also present of the cemented femoral component.
Other Names:
|
Active Comparator: Cemented Oxford Unicompartmental Knee Arthroplasty
Phase III Cemented Oxford Unicompartmental Knee Replacement (Biomet)
|
All patients will undergo the same surgical approach.
0.8mm diameter tantalum marker balls will be placed in the tibia and femur in all cases.
All cemented components will be secured using the same cement.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Radiostereometric Analysis Examination - Translations
Time Frame: Patients will be examined 60 months post surgery.
|
Patients will have weight-bearing stereoradiographs.
These stereoradiographs will be analysed using model-based radiostereometric analysis which will allow the migration of the components relative to the bone to be determined.
Three-dimensional translations will be measured in millimetres.
|
Patients will be examined 60 months post surgery.
|
Radiostereometric Analysis Examination - Maximum Total Point Motion
Time Frame: Patients will be examined at 3 months post surgery.
|
Patients will have weight-bearing stereoradiographs.
These stereoradiographs will be analysed using model-based radiostereometric analysis which will allow the migration of the components relative to the bone to be determined.
Maximum Total Point Motion (MTPM - defined as the length of the translation vector of the point of the component model that has migrated the most) will be measured in millimetres.
|
Patients will be examined at 3 months post surgery.
|
Radiostereometric Analysis Examination - Maximum Total Point Motion
Time Frame: Patients will be examined at 12 months post surgery.
|
Patients will have weight-bearing stereoradiographs.
These stereoradiographs will be analysed using model-based radiostereometric analysis which will allow the migration of the components relative to the bone to be determined.
Maximum Total Point Motion (MTPM - defined as the length of the translation vector of the point of the component model that has migrated the most) will be measured in millimetres.
|
Patients will be examined at 12 months post surgery.
|
Radiostereometric Analysis Examination - Maximum Total Point Motion
Time Frame: Patients will be examined at 24 months post surgery.
|
Patients will have weight-bearing stereoradiographs.
These stereoradiographs will be analysed using model-based radiostereometric analysis which will allow the migration of the components relative to the bone to be determined.
Maximum Total Point Motion (MTPM - defined as the length of the translation vector of the point of the component model that has migrated the most) will be measured in millimetres.
|
Patients will be examined at 24 months post surgery.
|
Radiostereometric Analysis Examination - Maximum Total Point Motion
Time Frame: Patients will be examined at 60 months post surgery.
|
Patients will have weight-bearing stereoradiographs.
These stereoradiographs will be analysed using model-based radiostereometric analysis which will allow the migration of the components relative to the bone to be determined.
Maximum Total Point Motion (MTPM - defined as the length of the translation vector of the point of the component model that has migrated the most) will be measured in millimetres.
|
Patients will be examined at 60 months post surgery.
|
Radiostereometric Analysis Examination - Maximum Total Point Motion
Time Frame: Patients will be examined at 120 months post surgery.
|
Patients will have weight-bearing stereoradiographs.
These stereoradiographs will be analysed using model-based radiostereometric analysis which will allow the migration of the components relative to the bone to be determined.
Maximum Total Point Motion (MTPM - defined as the length of the translation vector of the point of the component model that has migrated the most) will be measured in millimetres.
|
Patients will be examined at 120 months post surgery.
|
Radiographic Examination
Time Frame: Patients will be examined at 12 months post surgery.
|
Fluoroscopic imaging will be used to study the occurence of radiolucencies beneath the components.
Anteroposterior radiographs will be analysed to assess the presence and position of radiolucencies.
Radiolucencies will be graded as either 'no radiolucency present', 'partial radiolucency', or 'complete radiolucency'.
|
Patients will be examined at 12 months post surgery.
|
Radiographic Examination
Time Frame: Patients will be examined at 24 months post surgery.
|
Fluoroscopic imaging will be used to study the occurence of radiolucencies beneath the components.
Anteroposterior radiographs will be analysed to assess the presence and position of radiolucencies.
Radiolucencies will be graded as either 'no radiolucency present', 'partial radiolucency', or 'complete radiolucency'.
|
Patients will be examined at 24 months post surgery.
|
Radiographic Examination
Time Frame: Patients will be examined at 60 months post surgery.
|
Fluoroscopic imaging will be used to study the occurence of radiolucencies beneath the components.
Anteroposterior radiographs will be analysed to assess the presence and position of radiolucencies.
Radiolucencies will be graded as either 'no radiolucency present', 'partial radiolucency', or 'complete radiolucency'.
|
Patients will be examined at 60 months post surgery.
|
Radiographic Examination
Time Frame: Patients will be examined at 120 months post surgery.
|
Fluoroscopic imaging will be used to study the occurence of radiolucencies beneath the components.
Anteroposterior radiographs will be analysed to assess the presence and position of radiolucencies.
Radiolucencies will be graded as either 'no radiolucency present', 'partial radiolucency', or 'complete radiolucency'.
|
Patients will be examined at 120 months post surgery.
|
Clinical Assessment
Time Frame: Patients will be assessed pre-operatively.
|
Clinical assessment will involve documentation with the Oxford Knee Score.
The score will be calculated on a scale of 0 (worst) to 48 (best).
|
Patients will be assessed pre-operatively.
|
Clinical Assessment
Time Frame: Patients will be assessed at 12 months post surgery.
|
Clinical assessment will involve documentation with the Oxford Knee Score.
The score will be calculated on a scale of 0 (worst) to 48 (best).
|
Patients will be assessed at 12 months post surgery.
|
Clinical Assessment
Time Frame: Patients will be assessed at 24 months post surgery.
|
Clinical assessment will involve documentation with the Oxford Knee Score.
The score will be calculated on a scale of 0 (worst) to 48 (best).
|
Patients will be assessed at 24 months post surgery.
|
Clinical Assessment
Time Frame: Patients will be assessed at 60 months post surgery.
|
Clinical assessment will involve documentation with the Oxford Knee Score.
The score will be calculated on a scale of 0 (worst) to 48 (best).
|
Patients will be assessed at 60 months post surgery.
|
Clinical Assessment
Time Frame: Patients will be assessed at 120 months post surgery.
|
Clinical assessment will involve documentation with the Oxford Knee Score.
The score will be calculated on a scale of 0 (worst) to 48 (best).
|
Patients will be assessed at 120 months post surgery.
|
Radiostereometric Analysis Examination - Translations
Time Frame: Patients will be examined 3 months post surgery.
|
Patients will have weight-bearing stereoradiographs. These stereoradiographs will be analysed using model-based radiostereometric analysis which will allow the migration of the components relative to the bone to be determined. Three-dimensional translations will be measured in millimetres. The component position at the post-operative timepoint was used as the baseline for measurement of migration. Migration can be interpreted as:
|
Patients will be examined 3 months post surgery.
|
Radiostereometric Analysis Examination - Translations
Time Frame: Patients will be examined 6 months post surgery.
|
Patients will have weight-bearing stereoradiographs. These stereoradiographs will be analysed using model-based radiostereometric analysis which will allow the migration of the components relative to the bone to be determined. Three-dimensional translations will be measured in millimetres. The component position at the post-operative timepoint was used as the baseline for measurement of migration. Migration can be interpreted as:
|
Patients will be examined 6 months post surgery.
|
Radiostereometric Analysis Examination - Translations
Time Frame: Patients will be examined 12 months post surgery.
|
Patients will have weight-bearing stereoradiographs. These stereoradiographs will be analysed using model-based radiostereometric analysis which will allow the migration of the components relative to the bone to be determined. Three-dimensional translations will be measured in millimetres. The component position at the post-operative timepoint was used as the baseline for measurement of migration. Migration can be interpreted as:
|
Patients will be examined 12 months post surgery.
|
Radiostereometric Analysis Examination - Translations
Time Frame: Patients will be examined 24 months post surgery.
|
Patients will have weight-bearing stereoradiographs. These stereoradiographs will be analysed using model-based radiostereometric analysis which will allow the migration of the components relative to the bone to be determined. Three-dimensional translations will be measured in millimetres. The component position at the post-operative timepoint was used as the baseline for measurement of migration. Migration can be interpreted as:
|
Patients will be examined 24 months post surgery.
|
Radiostereometric Analysis Examination - Translations
Time Frame: Patients will be examined 120 months post surgery.
|
Patients will have weight-bearing stereoradiographs. These stereoradiographs will be analysed using model-based radiostereometric analysis which will allow the migration of the components relative to the bone to be determined. Three-dimensional translations will be measured in millimetres. The component position at the post-operative timepoint was used as the baseline for measurement of migration. Migration can be interpreted as:
|
Patients will be examined 120 months post surgery.
|
Radiostereometric Analysis Examination - Rotations
Time Frame: Patients will be examined at 3 months post surgery.
|
Patients will have weight-bearing stereoradiographs. These stereoradiographs will be analysed using model-based radiostereometric analysis which will allow the migration of the components relative to the bone to be determined. Three-dimensional rotations will be measured in degrees.The component position at the post-operative timepoint was used as the baseline for measurement of migration. Migration can be interpreted as: *For the Femoral Component* X Rotation: Positive (+ve) = Increased Flexion; Negative (-ve) = Decreased Flexion Y Rotation: Positive (+ve) = Internal Rotation; Negative (-ve) = External Rotation Z Rotation: Positive (+ve) = Valgus; Negative (-ve) = Varus *For the Tibial Component* X Rotation: Positive (+ve) = Reduced Slope; Negative (-ve) = Increased Slope Y Rotation: Positive (+ve) = Internal Rotation; Negative (-ve) = External Rotation Z Rotation: Positive (+ve) = Valgus; Negative (-ve) = Varus |
Patients will be examined at 3 months post surgery.
|
Radiostereometric Analysis Examination - Rotations
Time Frame: Patients will be examined at 6 months post surgery.
|
Patients will have weight-bearing stereoradiographs. These stereoradiographs will be analysed using model-based radiostereometric analysis which will allow the migration of the components relative to the bone to be determined. Three-dimensional rotations will be measured in degrees.The component position at the post-operative timepoint was used as the baseline for measurement of migration. Migration can be interpreted as:
|
Patients will be examined at 6 months post surgery.
|
Radiostereometric Analysis Examination - Rotations
Time Frame: Patients will be examined at 12 months post surgery.
|
Patients will have weight-bearing stereoradiographs. These stereoradiographs will be analysed using model-based radiostereometric analysis which will allow the migration of the components relative to the bone to be determined. Three-dimensional rotations will be measured in degrees.The component position at the post-operative timepoint was used as the baseline for measurement of migration. Migration can be interpreted as:
|
Patients will be examined at 12 months post surgery.
|
Radiostereometric Analysis Examination - Rotations
Time Frame: Patients will be examined at 24 months post surgery.
|
Patients will have weight-bearing stereoradiographs. These stereoradiographs will be analysed using model-based radiostereometric analysis which will allow the migration of the components relative to the bone to be determined. Three-dimensional rotations will be measured in degrees.The component position at the post-operative timepoint was used as the baseline for measurement of migration. Migration can be interpreted as:
|
Patients will be examined at 24 months post surgery.
|
Radiostereometric Analysis Examination - Rotations
Time Frame: Patients will be examined at 60 months post surgery.
|
Patients will have weight-bearing stereoradiographs. These stereoradiographs will be analysed using model-based radiostereometric analysis which will allow the migration of the components relative to the bone to be determined. Three-dimensional rotations will be measured in degrees.The component position at the post-operative timepoint was used as the baseline for measurement of migration. Migration can be interpreted as:
|
Patients will be examined at 60 months post surgery.
|
Radiostereometric Analysis Examination - Rotations
Time Frame: Patients will be examined at 120 months post surgery.
|
Patients will have weight-bearing stereoradiographs. These stereoradiographs will be analysed using model-based radiostereometric analysis which will allow the migration of the components relative to the bone to be determined. Three-dimensional rotations will be measured in degrees.The component position at the post-operative timepoint was used as the baseline for measurement of migration. Migration can be interpreted as:
|
Patients will be examined at 120 months post surgery.
|
Radiostereometric Analysis Examination - Maximum Total Point Motion
Time Frame: Patients will be assessed at 6 months post surgery.
|
Patients will have weight-bearing stereoradiographs.
These stereoradiographs will be analysed using model-based radiostereometric analysis which will allow the migration of the components relative to the bone to be determined.
Maximum Total Point Motion (MTPM - defined as the length of the translation vector of the point of the component model that has migrated the most) will be measured in millimetres.
|
Patients will be assessed at 6 months post surgery.
|
Collaborators and Investigators
Investigators
- Principal Investigator: David W Murray, MA, MD, FRCS, University of Oxford
Publications and helpful links
General Publications
- Kendrick BJ, Kaptein BL, Valstar ER, Gill HS, Jackson WF, Dodd CA, Price AJ, Murray DW. Cemented versus cementless Oxford unicompartmental knee arthroplasty using radiostereometric analysis: a randomised controlled trial. Bone Joint J. 2015 Feb;97-B(2):185-91. doi: 10.1302/0301-620X.97B2.34331.
- Campi S, Kendrick BJL, Kaptein BL, Valstar ER, Jackson WFM, Dodd CAF, Price AJ, Murray DW. Five-year results of a randomised controlled trial comparing cemented and cementless Oxford unicompartmental knee replacement using radiostereometric analysis. Knee. 2021 Jan;28:383-390. doi: 10.1016/j.knee.2020.09.003. Epub 2021 Jan 4.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PID7088
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteoarthritis, Knee
-
LifeBridge HealthMicroPort Orthopedics Inc.; Rubin Institute for Advanced OrthopedicsRecruitingKnee Osteoarthritis | Osteoarthritis, Knee | Knee Pain Chronic | Arthropathy of Knee Joint | Knee Disease | Osteoarthritis Knees Both | Osteoarthritis Knee Left | Osteoarthritis Knee RightUnited States
-
University Hospital, Clermont-FerrandSanofiCompletedKnee Osteoarthritis (Knee OA)France
-
Joseph E. BroylesCompletedDegenerative Lesion of Articular Cartilage of Knee | Degeneration; Articular Cartilage, Knee | Unilateral Primary Osteoarthritis of Knee | Osteoarthritis Knee
-
The Hong Kong Polytechnic UniversityCompleted
-
Federal University of São PauloCompletedKNEE OSTEOARTHRITISBrazil
-
Jiangsu XinChen-Techfields Pharma Co., LTD.Completed
-
Tianjin XinChen-Techfields Pharma Co., LTD.Completed
-
Eun Jung KimMinistry of Health & Welfare, Korea; Semyung UniversityUnknownOsteoarthritis KneeKorea, Republic of
-
Thammasat UniversityCompletedPrimary Knee OsteoarthritisThailand
-
Galderma R&DCompletedUnilateral Knee OsteoarthritisUnited Kingdom
Clinical Trials on Cementless Oxford Unicompartmental Knee Arthroplasty
-
Thammasat UniversityCompletedPrimary Gonarthrosis | Genu Recurvatum
-
Thammasat UniversityCompleted
-
Zimmer BiometDartmouth General HospitalCompleted
-
Zimmer BiometWithdrawnArthroplasty, Replacement, KneeAustralia
-
Anderson Orthopaedic Research InstituteRush University Medical CenterActive, not recruiting
-
Biomet Orthopedics, LLCCompletedOsteoarthritis | Avascular NecrosisUnited States
-
Karolinska InstitutetRecruitingUnicondylar- or Total Knee Replacement? Patient Satisfaction, Function and Muscle Mass (UKA or TKA?)Knee OsteoarthritisSweden
-
Laboratoires Bodycad Inc.TerminatedOsteoarthritis, KneeCanada
-
Societe dEtude, de Recherche et de FabricationRecruitingUnicompartmental Knee ArthroplastyFrance
-
Hvidovre University HospitalParker Research Institute; Frederiksberg University HospitalRecruitingArthritis | Knee Osteoarthritis | Surgery | Total Knee Arthroplasty | Unicompartmental Knee ArthroplastyDenmark